In this model, BCR-ABL transduced BM cells showed lower LSC numbers and a resultant impairment in their ability to initiate CML-like disease compared to controls [66]. This evidence concerns the gene ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive.